BioCentury | Feb 7, 2019
Tools & Techniques

Virtual compound library for high throughput computational drug discovery

...DRD4 - Dopamine D4 receptor Sandi Wong UCSF University of California San Francisco University of North Carolina at Chapel Hill AmpC beta lactamase Dopamine...
BioCentury | Sep 14, 2018
Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

...Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Zerbaxa ceftolozane/tazobactam Business: Infectious Molecular target: AmpC beta lactamase...
...treatment Status: Phase III data Milestone: NA Brian Moy Zerbaxa, ceftolozane/tazobactam (MK-7625A, cxa-201) Astellas Pharma Inc. Merck & Co. Inc. AmpC beta lactamase...
BioCentury | Sep 1, 2014
Clinical News

Ceftolozane/tazobactam: Additional Phase III data

...Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201 ) Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Sep 1, 2014
Clinical News

Ceftolozane/tazobactam: Additional Phase III data

...Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201 ) Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Dec 23, 2013
Clinical News

Ceftolozane/tazobactam: Phase III data

...Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201 ) Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Dec 9, 2013
Clinical News

Ceftolozane/tazobactam: Phase III data

...Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201 ) Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Jul 22, 2013
Clinical News

Ceftolozane/tazobactam: Phase III started

...Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Ceftolozane/tazobactam (formerly CXA-201 ) Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Oct 24, 2011
Clinical News

CXA-201: Phase III started

...about 780 patients. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CXA-201 Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Aug 8, 2011
Clinical News

CXA-201: Phase III started

...cUTI this quarter. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CXA-201 Business: Infectious Molecular target: AmpC beta lactamase...
BioCentury | Jun 20, 2011
Clinical News

CXA-201: Phase II data

...pneumonia in 2012. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Product: CXA-201 Business: Infectious Molecular target: AmpC beta lactamase...
Items per page:
1 - 10 of 11